JP2005529938A - 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 - Google Patents

癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 Download PDF

Info

Publication number
JP2005529938A
JP2005529938A JP2004510709A JP2004510709A JP2005529938A JP 2005529938 A JP2005529938 A JP 2005529938A JP 2004510709 A JP2004510709 A JP 2004510709A JP 2004510709 A JP2004510709 A JP 2004510709A JP 2005529938 A JP2005529938 A JP 2005529938A
Authority
JP
Japan
Prior art keywords
free radical
sesquiterpene
iron
cancer
radical generator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004510709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529938A5 (https=
Inventor
ヘンリー シー． ライ，
ナレンドラ ピー． シン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of JP2005529938A publication Critical patent/JP2005529938A/ja
Publication of JP2005529938A5 publication Critical patent/JP2005529938A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2004510709A 2002-06-06 2003-06-06 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 Pending JP2005529938A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38692802P 2002-06-06 2002-06-06
PCT/US2003/017791 WO2003103588A2 (en) 2002-06-06 2003-06-06 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer

Publications (2)

Publication Number Publication Date
JP2005529938A true JP2005529938A (ja) 2005-10-06
JP2005529938A5 JP2005529938A5 (https=) 2006-06-22

Family

ID=29736235

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004510709A Pending JP2005529938A (ja) 2002-06-06 2003-06-06 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
JP2004510713A Expired - Fee Related JP4440768B2 (ja) 2002-06-06 2003-06-06 アルテミシニン関連エンドペルオキシダーゼと鉄保有タンパク質と間の共有結合コンジュゲート、および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004510713A Expired - Fee Related JP4440768B2 (ja) 2002-06-06 2003-06-06 アルテミシニン関連エンドペルオキシダーゼと鉄保有タンパク質と間の共有結合コンジュゲート、および使用方法

Country Status (11)

Country Link
US (2) US20040058981A1 (https=)
EP (2) EP1531851B1 (https=)
JP (2) JP2005529938A (https=)
CN (3) CN101843904A (https=)
AU (2) AU2003251405A1 (https=)
BR (2) BR0312685A (https=)
CA (2) CA2488347A1 (https=)
NZ (2) NZ537113A (https=)
RU (2) RU2325156C2 (https=)
WO (1) WO2003103588A2 (https=)
ZA (1) ZA200500023B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523703A (ja) * 2005-10-20 2009-06-25 エピフアルマ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング アルテミシニン及びその誘導体を使用する良性色素性ホクロ（母斑）の処置及び予防
JP2012524772A (ja) * 2009-04-23 2012-10-18 ロンドンファーマ リミテッド ジヒドロアルテミシニンを含む舌下スプレー用製剤
US8522984B2 (en) 2009-05-07 2013-09-03 National University Corporation Okayama University Filter and air cleaner
JP2016500117A (ja) * 2012-11-29 2016-01-07 昆明制薬集団股▲分▼有限公司 アルテメーテル含有医薬組成物、製剤およびその使用
JP2021510715A (ja) * 2018-01-17 2021-04-30 セントジョージズ ホスピタル メディカル スクール 白血病治療のための併用療法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004029651D1 (de) 2003-02-12 2010-12-02 Univ Georgetown Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen
CA2537336C (en) * 2003-09-17 2013-02-26 Nektar Therapeutics Al, Corporation Multi-arm polymer prodrugs
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CN1255106C (zh) * 2003-09-26 2006-05-10 李国桥 复方青蒿素
US20050096369A1 (en) * 2003-11-04 2005-05-05 Hoang Ba X. Compositions and methods for treating cellular proliferation disorders
AU2004290983A1 (en) * 2003-11-19 2005-06-02 Vecta Ltd. Methods and compositions for the treatment of Helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
CN1311832C (zh) * 2005-01-12 2007-04-25 四川科伦药业股份有限公司 溴代二氢青蒿素的医药用途
US20060270863A1 (en) * 2005-05-27 2006-11-30 Amyris Biotechnologies Conversion of amorpha-4,11-diene to artemisinin and artemisinin precursors
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US20070231300A1 (en) * 2006-03-28 2007-10-04 Washington, University Of Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents
WO2008046109A2 (en) * 2006-10-13 2008-04-17 University Of Washington Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer
CN101583380B (zh) * 2006-11-30 2013-07-10 尼克塔治疗公司 用于制备聚合物轭合物的方法
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
CN101932598B (zh) * 2008-01-30 2016-12-21 皮里斯股份公司 具有对人c-met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
CN101323569B (zh) * 2008-07-24 2011-01-26 上海交通大学 倍半萜青蒿萜酯ae及其提取纯化方法
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
LT2349346T (lt) 2008-09-23 2019-09-25 Nektar Therapeutics Kamptotecino provaistų (pvz., peg-irinotekano) metronominio dozavimo būdas
KR20110075029A (ko) * 2008-10-21 2011-07-05 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료
GB2469791B (en) * 2009-04-23 2011-12-14 Londonpharma Ltd Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
CN102399142B (zh) * 2010-09-14 2014-09-24 华北制药集团新药研究开发有限责任公司 一类倍半萜酯化合物及其制备方法和用途
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
CN102727522B (zh) * 2011-04-08 2013-09-25 石雁羽 由溴代双氢青蒿素和Fe2+剂组成的复方双释胶囊制剂
CN103405779B (zh) * 2013-07-18 2015-09-30 江苏省血吸虫病防治研究所 一种预防血吸虫感染长效青蒿琥酯药物及其制备方法
CN109908137B (zh) * 2019-03-11 2022-02-18 江苏省人民医院（南京医科大学第一附属医院） 青蒿素在杀伤乳腺癌干细胞的药物中的应用
CN114983999A (zh) * 2022-06-09 2022-09-02 四川大学 一种青蒿素及其衍生物的新用途、验证方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
WO1997001548A1 (en) * 1995-06-29 1997-01-16 Hauser Chemical Research, Inc. Artemisinin dimer compounds having anticancer activity
WO1999065914A1 (fr) * 1998-06-17 1999-12-23 Shanghai Institute Of Materia Medica Derives de l'artemisinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000042046A1 (en) * 1999-01-12 2000-07-20 Hauser, Inc. Artemisinin analogs having antimalarial, antiproliferative, and antitumor activities and chemoselective methods of making the same
WO2001004123A2 (en) * 1999-07-09 2001-01-18 Ufc Limited Peroxide-based antimalarial compounds
JP2001527043A (ja) * 1997-12-30 2001-12-25 ハウサー，インコーポレイティド 抗マラリア、抗増殖及び抗腫瘍活性を有する、ｃ−１０炭素原子−置換されているアルテミシニン様トリオキサン化合物類
JP2002128784A (ja) * 2000-10-25 2002-05-09 Japan Science & Technology Corp 細胞侵入型励起一重項酸素発生化合物および該化合物を含む薬剤類

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916204A (en) * 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
FR2630329B1 (fr) * 1988-04-20 1991-07-05 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
RU2098407C1 (ru) * 1989-09-27 1997-12-10 Рон-Пуленк Рорер С.А. Способ получения пероксиацетальлактонового соединения (варианты) и лактон
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5472684A (en) * 1993-06-02 1995-12-05 Colgate Palmolive Company Oral compositions for plaque and gingivitis
US5869310A (en) * 1996-06-03 1999-02-09 Promega Corporation Isolated agarase enzyme from flavobacterium sp. strain NR19, cloned genes therefor, and expression thereof in transformed host cells
US6127405A (en) * 1998-07-10 2000-10-03 Council Of Scientific And Industrial Research Method for the use of alpha arteether as an anti-bacterial and anti-fungal agent
IN191696B (https=) * 1999-02-12 2003-12-20 Council Scient Ind Res
WO2002091992A2 (en) * 2001-05-16 2002-11-21 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
WO1997001548A1 (en) * 1995-06-29 1997-01-16 Hauser Chemical Research, Inc. Artemisinin dimer compounds having anticancer activity
JP2001527043A (ja) * 1997-12-30 2001-12-25 ハウサー，インコーポレイティド 抗マラリア、抗増殖及び抗腫瘍活性を有する、ｃ−１０炭素原子−置換されているアルテミシニン様トリオキサン化合物類
WO1999065914A1 (fr) * 1998-06-17 1999-12-23 Shanghai Institute Of Materia Medica Derives de l'artemisinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000042046A1 (en) * 1999-01-12 2000-07-20 Hauser, Inc. Artemisinin analogs having antimalarial, antiproliferative, and antitumor activities and chemoselective methods of making the same
WO2001004123A2 (en) * 1999-07-09 2001-01-18 Ufc Limited Peroxide-based antimalarial compounds
JP2002128784A (ja) * 2000-10-25 2002-05-09 Japan Science & Technology Corp 細胞侵入型励起一重項酸素発生化合物および該化合物を含む薬剤類

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523703A (ja) * 2005-10-20 2009-06-25 エピフアルマ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング アルテミシニン及びその誘導体を使用する良性色素性ホクロ（母斑）の処置及び予防
JP2012524772A (ja) * 2009-04-23 2012-10-18 ロンドンファーマ リミテッド ジヒドロアルテミシニンを含む舌下スプレー用製剤
US8522984B2 (en) 2009-05-07 2013-09-03 National University Corporation Okayama University Filter and air cleaner
JP2016500117A (ja) * 2012-11-29 2016-01-07 昆明制薬集団股▲分▼有限公司 アルテメーテル含有医薬組成物、製剤およびその使用
JP2021510715A (ja) * 2018-01-17 2021-04-30 セントジョージズ ホスピタル メディカル スクール 白血病治療のための併用療法

Also Published As

Publication number Publication date
JP2005535606A (ja) 2005-11-24
CA2488360A1 (en) 2003-12-18
BR0312685A (pt) 2005-09-06
CN101843904A (zh) 2010-09-29
ZA200500023B (en) 2005-10-20
CN1668293A (zh) 2005-09-14
EP1553935A2 (en) 2005-07-20
CN1668323A (zh) 2005-09-14
AU2003251405A1 (en) 2003-12-22
EP1531851B1 (en) 2011-12-14
JP4440768B2 (ja) 2010-03-24
EP1553935A4 (en) 2010-07-07
NZ537113A (en) 2007-01-26
RU2004139096A (ru) 2005-06-10
BR0311627A (pt) 2005-08-30
AU2003243418A1 (en) 2003-12-22
CA2488347A1 (en) 2003-12-18
EP1531851A4 (en) 2007-12-12
WO2003103588A2 (en) 2003-12-18
CN1313145C (zh) 2007-05-02
NZ537114A (en) 2007-02-23
RU2325156C2 (ru) 2008-05-27
EP1531851A2 (en) 2005-05-25
AU2003243418B2 (en) 2009-02-19
WO2003103588A3 (en) 2004-04-15
US20080119542A1 (en) 2008-05-22
US20040058981A1 (en) 2004-03-25
RU2004139090A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
JP2005529938A (ja) 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
AU2007203159B2 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
Zou et al. Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction
US7115563B2 (en) Composition and its therapeutic use
CN116549602A (zh) Awrk6多肽在制备治疗银屑病药物中的用途
KR101425303B1 (ko) 이소플라본을 포함하는 관절염 예방 및 치료용 약학적 조성물
EP3741366A1 (en) Composition comprising dunnione as effective ingredient for prevention or alleviation of hair loss
JP6441364B2 (ja) ジベンゾ−アルファ−ピロンを用いた体重増加制御
JPH06199694A (ja) 血圧安定化治療剤
ZA200500027B (en) Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer.
US20050119301A1 (en) Treatment of restenosis
JPH11501011A (ja) 神経保護薬としての縮合ベンゾチアゾール類の利用
WO2007091557A1 (ja) 肝癌治療又は予防用医薬組成物
HK40084623A (en) Use of glycerol phospholipids in the prevention and treatment of hyperlipidemia, atherosclerosis, non-alcoholic fatty liver and obesity
CN116173045A (zh) 甘油磷脂类化合物在预防和治疗高血脂、动脉粥样硬化、非酒精性脂肪肝和肥胖中的用途
US20230404953A1 (en) Compound for the reduction of white adipose tissue and the treatment of overweight and obesity
CN118985926A (zh) 一种具有改善线粒体功能的营养组合物及其应用
AU2008200518B2 (en) Treatment of restenosis
CN119258110A (zh) 用于防止和逆转在人体内的氧化应激期间的蛋白质糖化的微量营养素组合物
WO2022005848A1 (en) Combinations of carnosine and zinc for the treatment and prevention of viral infections
KR20050082448A (ko) 테트라하이드로베르베린을 유효성분으로 함유하는함유하는 동맥경화증, 고지혈증 및 간 질환의 예방 및치료용 조성물
JPH05246842A (ja) 貧血改善治療剤
KR19980066916A (ko) 간장의 항섬유화 작용을 가지는 약학적 조성물
MXPA97004669A (en) Use of nebivolol as an antiaterogen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100622